Cancer
Researchers from University of Barcelona discuss findings in cancer
Published in Cancer Weekly, September 4th, 2007
According to a study from Barcelona, Spain, "The proliferation signal inhibitors [PSIs; mammalian target of rapamycin (mTOR) inhibitors] are widely used for immunosuppression in transplant recipients. Alongside their immunosuppressive properties, PSIs also have substantial anti-neoplastic activity, as a result of their inhibition of cellular signalling pathways involved in critical functions such as cell division, T-cell activation, invasion and growth factor production."
"In vitro and in vivo studies have shown that PSIs can prevent the growth of experimentally transformed cells and tumour-derived cell lines, and can also increase the sensitivity of cells to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2007-09-04)
More Articles from Cancer Weekly
- Biomedicine
The St. Baldrick's Foundation Awards $4.5 Million Grant to the Children's Oncology Group - Bladder Cancer
Bioniche Provides Update on Refractory Bladder Cancer Trial - Breast Cancer
Chicago Cubs, National City Searching for Breast Cancer Survivors To Honor Before Cubs vs. Pirates Home Game - Breast Cancer
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge) in Advanced Breast Cancer Patients - Breast Cancer
Des Moines Affiliate of Susan G. Komen for the Cure, Elizabeth Edwards, Breast Cancer Survivors and Activists Called on Policymakers to Address Injustice and Unfairness in Breast Cancer Incidence and Mortality - Breast Cancer
Fat bastard Wine Wears Pink Ribbon in Support of Breast Cancer - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
